Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)
Phase of Trial: Phase I
Latest Information Update: 24 May 2018
At a glance
- Drugs Cabozantinib (Primary) ; Nivolumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 16 Apr 2018 Status changed from not yet recruiting to recruiting.
- 02 Mar 2018 Planned End Date changed from 1 Dec 2021 to 1 Mar 2022.
- 02 Mar 2018 Planned primary completion date changed from 1 Dec 2021 to 1 Mar 2022.